EyePoint Pharmaceuticals, Inc. has initiated a public offering of $150 million of its common stock. The underwriters have an option to purchase an additional $22.5 million. Proceeds will fund the development of DURAVYU™ for wet AMD and DME, and support pipeline initiatives. J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are managing the offering. EyePoint plans to use the net proceeds for clinical development and general corporate purposes. The securities are offered under an effective shelf registration statement. EyePoint is a biopharmaceutical company focused on retinal diseases, with DURAVYU™ in pivotal Phase 3 trials for wet AMD.

Read more at GlobeNewswire: EyePoint Announces Proposed Public Offering of Common